Condensed Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue:
Biocatalyst product sales	$ 3,076	$ 2,985
Biocatalyst research and development	2,197	2,146
Revenue sharing arrangement	1,525	1,943
Total revenue	6,798	7,074
Costs and operating expenses:
Cost of biocatalyst product sales	1,456	2,524
Research and development	5,293	4,834
Selling, general and administrative	5,578	6,112
Total costs and operating expenses	12,327	13,470
Loss from operations	(5,529)	(6,396)
Interest income	4	9
Other expenses	(25)	(118)
Loss before income taxes	(5,550)	(6,505)
Provision for (benefit from) income taxes	12	(130)
Net loss	$ (5,562)	$ (6,375)
Net loss per share, basic and diluted (dollars per share)	$ (0.14)	$ (0.17)
Weighted average common shares used in computing net loss per share, basic and diluted (shares)	38,779	38,506